SCHEMBL15840784

SCHEMBL15840784

CCCc1c(C)nc(Nc2nc(C)c3cccc(OC)c3n2)[nH]c1=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.56
USP2 O75604 2/20 0.56
TSHR P16473 1/20 0.56
ALDH1A1 P00352 5/20 0.52
KMT2A Q03164 4/20 0.52
LMNA P02545 4/20 0.52
RAB9A P51151 3/20 0.52
MEN1 O00255 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.51
PKM P14618 1/20 0.51
CREBBP Q92793 1/20 0.51
HSD17B10 Q99714 2/20 0.51
KDM4E B2RXH2 3/20 0.48
HTT P42858 5/20 0.47
NPSR1 Q6W5P4 4/20 0.47
XBP1 P17861 2/20 0.47
TDP2 O95551 1/20 0.44
NPC1 O15118 1/20 0.44
CLK1 P49759 1/20 0.44
AURKA O14965 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15840763 0.92 ALDH1A1 (0.62) MAPTUSP2TSHRALDH1A1KMT2A
SCHEMBL15840587 0.87 MAPT (0.52) MAPTUSP2TSHRALDH1A1KMT2A
SCHEMBL15840599 0.86 ALDH1A1 (0.50) MAPTUSP2TSHRALDH1A1KMT2A
SCHEMBL15840598 0.85 ALDH1A1 (0.59) MAPTUSP2TSHRALDH1A1KMT2A
SCHEMBL22853716 0.79 ALDH1A1 (0.52) MAPTALDH1A1KMT2ALMNARAB9A
SCHEMBL15840589 0.79 AURKA (0.46) MAPTUSP2TSHRALDH1A1KMT2A
SCHEMBL15840824 0.78 STAT3 (0.55) MAPTUSP2TSHRALDH1A1KMT2A
SCHEMBL15840698 0.78 AURKA (0.46) MAPTUSP2TSHRALDH1A1KMT2A
SCHEMBL15840757 0.78 KMT2A (0.62) MAPTUSP2TSHRALDH1A1KMT2A
SCHEMBL15840582 0.77 ALPL (0.65) MAPTALDH1A1KMT2ALMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140179681-A1 METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT Errico, Joseph P. (US) 2014-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140179681-A1 METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT EGFR, ERBB2, ERBB3 MAPT 1076/4885USP2 1628/4885TSHR 3057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.